Numerous ICIs have been studied for NKTCL, including the dual-targeting anti-PD1/PD-L1 antibody IBI318; the PD-1 mAbs pembrolizumab, sintilimab, tislelizumab, and toripalimab; and the PD-L1 mAbs sugemalimab and avelumab. Here, PDCD1 is linked to extranodal nasal NK/T cell lymphoma.